A Two-in-One Nanoparticle That Lights Up Brain Cancer, Then Destroys What’s Left

Glioblastoma has a grim reputation among brain cancers, and for good reason. It tends to weave itself into surrounding healthy brain tissue, which makes complete surgical removal nearly impossible without risking damage to areas surgeons need to protect. The blood-brain barrier compounds the problem, blocking most drugs and limiting how well radiotherapy can reach the tumor. Put those two obstacles together and it’s easier to understand why the five-year survival rate for glioblastoma sits at only around 7 percent.

A team from the University of Technology Sydney, Harvard Medical School, and Henan University has now developed a nanoparticle platform, published in Science Translational Medicine, that tries to tackle both of glioblastoma’s core problems with a single material, one that does its job in two separate acts.

One Material, Two Jobs

At the heart of the system is an ultra-thin two-dimensional sheet, precisely decorated with individual atoms using a fabrication technique borrowed from semiconductor manufacturing. That structure gives the material a kind of dual identity: during surgery, it acts as a highly sensitive imaging agent, and once the visible tumor has been removed, the very same material can be reactivated to mop up what’s left behind.

Both roles are triggered by the same near-infrared light, which is what allows one platform to switch between guiding the surgeon’s hand and finishing the job afterward.

Seeing Tumor Clusters Surgeons Would Otherwise Miss

During the operation, a fluorescent dye engineered into the nanosheet glows under a near-infrared wavelength invisible to the naked eye. According to Dr. Bingyang Shi, who led the work, this allows surgeons to make out individual tumor cell clusters as small as 44 micrometers, a level of resolution beyond what current clinical imaging tools can offer. A targeting molecule attached to the material also helps it cross the blood-brain barrier and accumulate specifically in glioma cells, rather than diffusing indiscriminately through healthy tissue.

Then, a Second Act: Cleaning Up What Surgery Couldn’t Reach

Once the visible tumor is out, the same nanomaterial gets a second job. Applied directly into the surgical cavity and reactivated with the same light, it converts the tumor’s own hydrogen peroxide into oxygen, undercutting the low-oxygen environment that glioblastoma cells often rely on to resist treatment. At the same time, the light triggers heat and reactive molecules that go after the microscopic cancer cells surgery physically couldn’t remove.

That second act matters because glioblastoma’s most dangerous trait isn’t the tumor mass itself, but the scattered, invisible cells it leaves behind, the ones responsible for most recurrences.

Encouraging Numbers, With a Big Caveat

In mouse models of glioblastoma, the treatment meaningfully cut down tumor recurrence after surgery. Every treated mouse was still alive 60 days later, compared with a median survival of just 42 days among mice that had surgery alone. Follow-up testing turned up no detectable neurological or motor problems tied to the treatment.

“Professor Shi is careful to frame this as early, animal-only research, encouraging, but still a long way from clinical use, with imaging and therapeutic performance yet to be confirmed at the scale of a human brain.”

If the results hold up through further testing, the long-term hope is fairly intuitive: surgeons could see more of the tumor while operating, and treat more of what’s left behind once they’re done, chipping away at recurrence, which remains one of the toughest problems in glioblastoma care.

Original paper: Shangguan, P. et al. (2026). Spatiotemporal-switchable 2D NIR-II single-atom nanozyme for single-cell–level surgical navigation and glioblastoma phototherapy. Science Translational Medicine, 18(861). 

Source: A Two-in-One Nanoparticle That Lights Up Brain Cancer, Then Destroys What’s Left